Evidence map›Paper›PMID 37199902›Full record

ReviewCurrent hypertension reports2023

Sexual Dimorphic Interplays Between Gut Microbiota and Antihypertensive Drugs.

Pritam Bardhan, Tao Yang

Open access · bronzeAbstract readReview
In one paragraph

Review in Current hypertension reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 14 citations in OpenAlex.

  1. Placebo-resistant gut bacteria:Frontiers in cellular and infection microbiology · 2024
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. The probioticGut microbes · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Revisiting sex as a biological variable in hypertension research.The Journal of clinical investigation · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Pritam BardhanDepartment of Physiology and Pharmacology, Center for Hypertension and Precision Medicine, College of Medicine and Life Sciences, The University of Toledo, Health Science Campus Block Health Science Bldg, Room 310, 3000 Arlington Ave., Toledo, OH, 43614, USA.
Tao YangDepartment of Physiology and Pharmacology, Center for Hypertension and Precision Medicine, College of Medicine and Life Sciences, The University of Toledo, Health Science Campus Block Health Science Bldg, Room 310, 3000 Arlington Ave., Toledo, OH, 43614, USA. Tao.Yang2@utoledo.edu.ORCID 0000-0002-4182-9793
University of Toledo · US

Funding

Role of gut commensal Coprococcus comes in angiotensin-converting enzyme inhibitor resistant hypertensionR21AG079357 · NIA · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI YANG, TAO · 2022 to 2023
$425k
NIA NIH HHS R21 AG079357NIA NIH HHS R21AG079357
6 · The paper itself

Abstract

purpose of the reviewThe purpose of this study is to review the current literature regarding gut microbiota in blood pressure regulation and its interactions with antihypertensive drugs and to discuss how sex differences in gut microbiota contribute to sexual dimorphism of hypertension and treatment. RECENT

findingsThe significance of gut microbiota in blood pressure regulation and hypertension etiology is growingly recognized. Targeting the dysbiotic microbiota is proposed to be a new therapeutic method. Recently, a few studies demonstrated that the gut microbiota is highly involved in the modulation of the efficacy of antihypertensive drugs, suggesting a novel mechanism by which gut microbiota plays a role in treatment-resistant hypertension. Furthermore, studies on sex differences in gut microbiota, etiology of hypertension, and sex bias in prescription of antihypertensive medications have revealed promising avenues in sexual dimorphism-based precision medicine. However, no scientific questions are ever raised on how sex differences in gut microbiota contribute to the sex specific responses of certain classes of antihypertensive drugs. Given the dynamics and complexity among individuals, precision medicine is proposed of great potential. We review current knowledge on the interactions between gut microbiota, hypertension, and antihypertensive drugs with an emphasis on sex as a crucial determinant. We propose that sex differences in gut microbiota be a research focus to advance our understanding of hypertension management.

Indexed as

Gastrointestinal MicrobiomeHypertensionMicrobiotaAntihypertensive AgentsBlood PressureFemaleHumansMaleAntihypertensive AgentsAntihypertensive drugsGut microbiotaHypertensionResistant hypertensionSex differences

Identifiers

PMID37199902
PMCPMC10193343
OpenAlexW4377010860

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.